Recombinant Factor Viii News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Octapharma
Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A
Thursday, February 18, 2021 4:01PM IST (10:31AM GMT)
 
LACHEN, Switzerland:
 
Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq
® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal
Thrombosis and Haemostasis (Liesner RJ et al. “Simoctocog Alfa (Nuwiq
®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).
 
The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess ....

India General , United States , United Kingdom , City Of , Nordrhein Westfalen , Larisa Belyanskaya , Anthony Chan , Ivana Spotakova , Olaf Walter , Professor Of Paediatrics At Mcmaster University , Octapharma Ag International Business Unit , Previously Untreated Patients , Severe Haemophilia , Final Results , Great Ormond Street Hospital , Board Member , Mcmaster University , Adv Hematol , Media Contact , Business Unit , Haemophilia A , Medical Journal , Thrombosis And Haemostasis , Simoctocog Alfa , Dr Ri Liesner , Fviii Therapy ,